Originally developed to treat type 2 diabetes, these medications were FDA-approved for chronic weight management after clinical trials showed remarkable weight loss results
These differences are not only statistically significant but also clinically relevant
doi:10.1124/jpet.108.149211 Raun K, Hansen BS, Johansen NL, et al
evoke and evoke+: design of two large-scale, double-blind, placebocontrolled, phase 3 studies evaluating efficacy, safety, and tolerability of semaglutide in early-stage symptomatic Alzheimers disease
This is due to saturation of the IGF-1R receptors, resulting in the remaining IGF-1 circulating in the blood attaching to bone and gastrointestinal tissue [1, 16]